Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Cipla

Next Previous
Search
Drug Profile

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Cipla

Alternative Names: Dolutegravir/lamivudine/tenofovir - Cipla; TDF/3TC/DTG - Cipla; Tenofovir disoproxil fumarate/dolutegravir/lamivudine - Cipla; Tenofovir disoproxil fumarate/lamivudine/dolutegravir - Cipla; TLD - Cipla

Latest Information Update: 28 Sep 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cipla
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered HIV-1 infections

Most Recent Events

  • 28 Sep 2018 Chemical structure information added
  • 11 Sep 2018 Registered for HIV-1 infections (First-line therapy) in South Africa (PO)
  • 11 Sep 2018 South African Health Products Regulatory Authority (SAHPRA) approves dolutegravir/lamivudine/tenofovir disoproxil fumarate as first line therapy for the treatment of HIV-1 infections in South Africa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top